Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

mepha pharma ag - clindamycinum - capsule - clindamycinum 150 mg ut clindamycini hydrochloridum, amylum pregelificatum, talcum, magnesii stearas, lactosum monohydricum 78.8 mg, kapselhülle: gelatina, e 171, e 172 (flavum), e 172 (rubrum), e 172 (nigrum), pro capsula. - malattie infettive - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

mepha pharma ag - clindamycinum - capsule - clindamycinum 300 mg ut clindamycini hydrochloridum, amylum pregelificatum, talcum, magnesii stearas, lactosum monohydricum 147.67 mg, kapselhülle: gelatina, e 171, e 172 (flavum), e 172 (rubrum), e 172 (nigrum), pro capsula. - malattie infettive - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

pfizer ag - clindamycinum - granulato per la realizzazione di una soluzione orale - clindamycinum 75 mg ut clindamycini-2 palmitatis hydrochloridum, simeticonum, poloxamerum 188, saccharum 1.8 g, aromatica (kirschen), e 214 0.6 mg ad granulatum corresp. solutio reconstituta 5 ml. - malattie infettive - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

pfizer ag - clindamycinum - capsule rigide - clindamycinum 150 mg ut clindamycini hydrochloridum, maydis amylum, talcum, magnesii stearas, lactosum monohydricum max. 224.13 mg, kapselhülle: gelatina, e 171, drucktinte: lacca, e 172 (nigrum), propylenglycolum, ammoniae solutio concentrata, kalii hydroxidum, pro capsula. - malattie infettive - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

pfizer ag - clindamycinum - capsule rigide - clindamycinum 300 mg ut clindamycini hydrochloridum, maydis amylum, talcum, magnesii stearas, lactosum monohydricum max. 283.27 mg, kapselhülle: gelatina, e 171, drucktinte: lacca, e 172 (nigrum), propylenglycolum, ammoniae solutio concentrata, kalii hydroxidum, pro capsula. - malattie infettive - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

helvepharm ag - clindamycinum - capsule - clindamycinum 150 mg ut clindamycini hydrochloridum, lactosum monohydricum 214.08 mg, maydis amylum, talcum, magnesii stearas, kapselhülle: gelatina, e 171, drucktinte: lacca, e 172 (nigrum), propylenglycolum, pro capsula. - malattie infettive - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

helvepharm ag - clindamycinum - capsule - clindamycinum 300 mg ut clindamycini hydrochloridum, lactosum monohydricum 283.24 mg, maydis amylum, talcum, magnesii stearas, kapselhülle: gelatina, e 171, drucktinte: lacca, e 172 (nigrum), propylenglycolum, pro capsula. - malattie infettive - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

sandoz pharmaceuticals ag - clindamycinum - capsule - clindamycinum 150 mg ut clindamycini hydrochloridum, amylum pregelificatum, talcum, magnesii stearas, lactosum monohydricum 78.8 mg, kapselhülle: gelatina, e 171, e 172 (flavum), e 172 (rubrum), e 172 (nigrum), pro capsula. - malattie infettive - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

sandoz pharmaceuticals ag - clindamycinum - capsule - clindamycinum 300 mg ut clindamycini hydrochloridum, amylum pregelificatum, talcum, magnesii stearas, lactosum monohydricum 147.67 mg, kapselhülle: gelatina, e 171, e 172 (flavum), e 172 (rubrum), e 172 (nigrum), pro capsula. - malattie infettive - synthetika

Svizzera - italiano - Swissmedic (Swiss Agency for Therapeutic Products)

mepha pharma ag - clindamycinum - konzentrat zur herstellung einer infusionslösung i.v. / injektionslösung i.m. - clindamycinum 600 mg ut clindamycini phosphas, dinatrii edetas, natrii hydroxidum, alcohol benzylicus 37.8 mg, aqua ad iniectabile ad solutionem pro 4 ml corresp. natrium max. 34.04 mg. - malattie infettive - synthetika